Skip to main content
Erschienen in: Inflammopharmacology 6/2019

29.04.2019 | Original Article

Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis

verfasst von: Philipp Guenthoer, Kerstin Fuchs, Gerald Reischl, Leticia Quintanilla-Martinez, Irene Gonzalez-Menendez, Stefan Laufer, Bernd J. Pichler, Manfred Kneilling

Erschienen in: Inflammopharmacology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Mitogen-activated protein kinase (MAPK) signaling plays an important role in inflammatory diseases such as rheumatoid arthritis (RA).The aim of our study was to elucidate the therapeutic potential of the highly selective p38 MAPK inhibitor Skepinone-L and the dual inhibitor LN 950 (p38 MAPK and JNK 3) in the K/BxN serum transfer model of RA. Additionally, we aimed to monitor MAPK treatment non-invasively in vivo using the hypoxia tracer [18F]fluoromisonidazole ([18F]FMISO) and positron emission tomography (PET).

Methods

To induce experimental arthritis, we injected glucose-6-phosphate isomerase autoantibody-containing serum in BALB/c mice. MAPK inhibitor or Sham treatment was administered per os once daily. On days 3 and 6 after arthritis induction, we conducted PET imaging with [18F]FMISO. At the end of the experiment, ankles were harvested for histopathological analysis.

Results

Skepinone-L and LN 950 were applicable to suppress the severity of experimental arthritis confirmed by reduced ankle swelling and histopathological analysis. Skepinone-L (3.18 ± 0.19 mm) and LN 950 (3.40 ± 0.13 mm) treatment yielded a significantly reduced ankle thickness compared to Sham-treated mice (3.62 ± 0.11 mm) on day 5 after autoantibody transfer, a time-point characterized by severe arthritis. Hypoxia imaging with [18F]FMISO revealed non-conclusive results and might not be an appropriate tool to monitor MAPK therapy in experimental RA.

Conclusion

Both the selective p38 MAPK inhibitor Skepinone-L and the dual (p38 MAPK and JNK 3) inhibitor LN 950 exhibited significant therapeutic effects during experimental arthritis. Thus, our study contributes to the ongoing discussion on the use of p38 MAPK as a potential target in RA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Aho O-M, Finnilä M, Thevenot J, Saarakkala S, Lehenkari P (2017) Subchondral bone histology and grading in osteoarthritis. PLoS One 12:e0173726PubMedPubMedCentral Aho O-M, Finnilä M, Thevenot J, Saarakkala S, Lehenkari P (2017) Subchondral bone histology and grading in osteoarthritis. PLoS One 12:e0173726PubMedPubMedCentral
Zurück zum Zitat Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13:679–692PubMed Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13:679–692PubMed
Zurück zum Zitat Bevaart L, Vervoordeldonk MJ, Tak PP (2010) Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum 62:2192–2205PubMed Bevaart L, Vervoordeldonk MJ, Tak PP (2010) Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum 62:2192–2205PubMed
Zurück zum Zitat Burnette BL, Selness S, Devraj R, Jungbluth G, Kurumbail R, Stillwell L, Anderson G, Mnich S, Hirsch J, Compton R, De Ciechi P, Hope H, Hepperle M, Keith RH, Naing W, Shieh H, Portanova J, Zhang Y, Zhang J, Leimgruber RM, Monahan J (2009) SD0006: a potent, selective and orally available inhibitor of p38 kinase. Pharmacology 84:42–60PubMedPubMedCentral Burnette BL, Selness S, Devraj R, Jungbluth G, Kurumbail R, Stillwell L, Anderson G, Mnich S, Hirsch J, Compton R, De Ciechi P, Hope H, Hepperle M, Keith RH, Naing W, Shieh H, Portanova J, Zhang Y, Zhang J, Leimgruber RM, Monahan J (2009) SD0006: a potent, selective and orally available inhibitor of p38 kinase. Pharmacology 84:42–60PubMedPubMedCentral
Zurück zum Zitat Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858–864PubMed Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858–864PubMed
Zurück zum Zitat Chaudhari AJ, Bowen SL, Burkett GW, Packard NJ, Godinez F, Joshi AA, Naguwa SM, Shelton DK, Hunter JC, Boone JM, Buonocore MH, Badawi RD (2010) High-resolution (18)F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging 37:1047PubMedPubMedCentral Chaudhari AJ, Bowen SL, Burkett GW, Packard NJ, Godinez F, Joshi AA, Naguwa SM, Shelton DK, Hunter JC, Boone JM, Buonocore MH, Badawi RD (2010) High-resolution (18)F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging 37:1047PubMedPubMedCentral
Zurück zum Zitat Choy EH, Kavanaugh AF, Jones SA (2013) The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 9:154–163PubMed Choy EH, Kavanaugh AF, Jones SA (2013) The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 9:154–163PubMed
Zurück zum Zitat Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP (2009) Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60:335–344PubMed Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP (2009) Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60:335–344PubMed
Zurück zum Zitat Corr M, Boyle DL, Ronacher LM, Lew BR, Van Baarsen LG, Tak PP, Firestein GS (2011) Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis. Ann Rheum Dis 70:858–863PubMedPubMedCentral Corr M, Boyle DL, Ronacher LM, Lew BR, Van Baarsen LG, Tak PP, Firestein GS (2011) Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis. Ann Rheum Dis 70:858–863PubMedPubMedCentral
Zurück zum Zitat Damjanov N, Kauffman RS, Spencer-Green GT (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60:1232–1241PubMed Damjanov N, Kauffman RS, Spencer-Green GT (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60:1232–1241PubMed
Zurück zum Zitat Davis RJ (2000) Signal transduction by the JNK Group of MAP kinases. Cell 103:239–252PubMed Davis RJ (2000) Signal transduction by the JNK Group of MAP kinases. Cell 103:239–252PubMed
Zurück zum Zitat Denninger K, Rasmussen S, Larsen JM, Ørskov C, Seier Poulsen S, Sørensen P, Christensen JP, Illges H, Ødum N, Labuda T (2011) JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis. Am J Pathol 179:1884–1893PubMedPubMedCentral Denninger K, Rasmussen S, Larsen JM, Ørskov C, Seier Poulsen S, Sørensen P, Christensen JP, Illges H, Ødum N, Labuda T (2011) JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis. Am J Pathol 179:1884–1893PubMedPubMedCentral
Zurück zum Zitat Ding C (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs 7:1020–1025PubMed Ding C (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs 7:1020–1025PubMed
Zurück zum Zitat Ebelt ND, Cantrell MA, Van Den Berg CL (2013) c-Jun N-terminal kinases mediate a wide range of targets in the metastatic cascade. Genes Cancer 4:378–387PubMedPubMedCentral Ebelt ND, Cantrell MA, Van Den Berg CL (2013) c-Jun N-terminal kinases mediate a wide range of targets in the metastatic cascade. Genes Cancer 4:378–387PubMedPubMedCentral
Zurück zum Zitat Feng YJ, Li YY (2011) The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease. J Dig Dis 12:327–332PubMed Feng YJ, Li YY (2011) The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease. J Dig Dis 12:327–332PubMed
Zurück zum Zitat Finnegan A, Kaplan CD, Cao Y, Eibel H, Glant TT, Zhang J (2003) Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Therapy 5:R18–R24 Finnegan A, Kaplan CD, Cao Y, Eibel H, Glant TT, Zhang J (2003) Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Therapy 5:R18–R24
Zurück zum Zitat Fuchs K, Kohlhofer U, Quintanilla-Martinez L, Lamparter D, Kotter I, Reischl G, Rocken M, Pichler BJ, Kneilling M (2013) In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3′-deoxy-3′-18f-fluorothymidine and small-animal PET. J Nucl Med 54:151–158PubMed Fuchs K, Kohlhofer U, Quintanilla-Martinez L, Lamparter D, Kotter I, Reischl G, Rocken M, Pichler BJ, Kneilling M (2013) In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3′-deoxy-3′-18f-fluorothymidine and small-animal PET. J Nucl Med 54:151–158PubMed
Zurück zum Zitat Fuchs K, Kuehn A, Mahling M, Guenthoer P, Hector A, Schwenck J, Hartl D, Laufer S, Kohlhofer U, Quintanilla-Martinez L, Reischl G, Rocken M, Pichler BJ, Kneilling M (2017) In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of hypoxia-inducible factor and enhanced reactive oxygen species generation. J Nucl Med 58:853–860PubMed Fuchs K, Kuehn A, Mahling M, Guenthoer P, Hector A, Schwenck J, Hartl D, Laufer S, Kohlhofer U, Quintanilla-Martinez L, Reischl G, Rocken M, Pichler BJ, Kneilling M (2017) In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of hypoxia-inducible factor and enhanced reactive oxygen species generation. J Nucl Med 58:853–860PubMed
Zurück zum Zitat Fukushima A, Boyle DL, Corr M, Firestein GS (2010) Kinetic analysis of synovial signalling and gene expression in animal models of arthritis. Ann Rheum Dis 69:918–923PubMed Fukushima A, Boyle DL, Corr M, Firestein GS (2010) Kinetic analysis of synovial signalling and gene expression in animal models of arthritis. Ann Rheum Dis 69:918–923PubMed
Zurück zum Zitat Genovese MC (2009) Inhibition of p38: has the fat lady sung? Arthritis Rheum 60:317–320PubMed Genovese MC (2009) Inhibition of p38: has the fat lady sung? Arthritis Rheum 60:317–320PubMed
Zurück zum Zitat Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE (2011) A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 38:846–854PubMed Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE (2011) A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 38:846–854PubMed
Zurück zum Zitat Goldstein DM, Kuglstatter A, Lou Y, Soth MJ (2010) Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 53:2345–2353PubMed Goldstein DM, Kuglstatter A, Lou Y, Soth MJ (2010) Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 53:2345–2353PubMed
Zurück zum Zitat Guma M, Firestein GS (2012) c-Jun N-terminal kinase in inflammation and rheumatic diseases. Open Rheumatol J 6:220–231PubMedPubMedCentral Guma M, Firestein GS (2012) c-Jun N-terminal kinase in inflammation and rheumatic diseases. Open Rheumatol J 6:220–231PubMedPubMedCentral
Zurück zum Zitat Guma M, Hammaker D, Topolewski K, Corr M, Boyle DL, Karin M, Firestein GS (2012) Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum 64:2887–2895PubMedPubMedCentral Guma M, Hammaker D, Topolewski K, Corr M, Boyle DL, Karin M, Firestein GS (2012) Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum 64:2887–2895PubMedPubMedCentral
Zurück zum Zitat Hammaker D, Firestein GS (2010) “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis 69(Suppl 1):i77–i82PubMedPubMedCentral Hammaker D, Firestein GS (2010) “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis 69(Suppl 1):i77–i82PubMedPubMedCentral
Zurück zum Zitat Hammaker D, Topolewski K, Edgar M, Yoshizawa T, Fukushima A, Boyle DL, Burak EC, Sah RL, Firestein GS (2012) Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice. Arthritis Rheum 64:678–687PubMedPubMedCentral Hammaker D, Topolewski K, Edgar M, Yoshizawa T, Fukushima A, Boyle DL, Burak EC, Sah RL, Firestein GS (2012) Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice. Arthritis Rheum 64:678–687PubMedPubMedCentral
Zurück zum Zitat Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73–81PubMedPubMedCentral Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73–81PubMedPubMedCentral
Zurück zum Zitat Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR (2008) Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 327:610–619PubMed Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR (2008) Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 327:610–619PubMed
Zurück zum Zitat Horsfall AC, Butler DM, Marinova L, Warden PJ, Williams RO, Maini RN, Feldmann M (1997) Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 159:5687–5696PubMed Horsfall AC, Butler DM, Marinova L, Warden PJ, Williams RO, Maini RN, Feldmann M (1997) Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 159:5687–5696PubMed
Zurück zum Zitat Hu P, Nebreda AR, Liu Y, Carlesso N, Kaplan M, Kapur R (2012) p38alpha protein negatively regulates T helper type 2 responses by orchestrating multiple T cell receptor-associated signals. J Biol Chem 287:33215–33226PubMedPubMedCentral Hu P, Nebreda AR, Liu Y, Carlesso N, Kaplan M, Kapur R (2012) p38alpha protein negatively regulates T helper type 2 responses by orchestrating multiple T cell receptor-associated signals. J Biol Chem 287:33215–33226PubMedPubMedCentral
Zurück zum Zitat Hu F, Shi L, Mu R, Zhu J, Li Y, Ma X, Li C, Jia R, Yang D, Li Y, Li Z (2013) Hypoxia-inducible factor-1alpha and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis. PLoS One 8:e72650PubMedPubMedCentral Hu F, Shi L, Mu R, Zhu J, Li Y, Ma X, Li C, Jia R, Yang D, Li Y, Li Z (2013) Hypoxia-inducible factor-1alpha and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis. PLoS One 8:e72650PubMedPubMedCentral
Zurück zum Zitat Inoue T, Boyle DL, Corr M, Hammaker D, Davis RJ, Flavell RA, Firestein GS (2006) Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc Natl Acad Sci USA 103:5484–5489PubMed Inoue T, Boyle DL, Corr M, Hammaker D, Davis RJ, Flavell RA, Firestein GS (2006) Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc Natl Acad Sci USA 103:5484–5489PubMed
Zurück zum Zitat Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, Benoist C (2002) Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196:77–85PubMedPubMedCentral Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, Benoist C (2002) Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196:77–85PubMedPubMedCentral
Zurück zum Zitat Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 62:1128–1143 Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 62:1128–1143
Zurück zum Zitat Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R, Meacham RB, Koul HK (2009) Hypoxia associated p38 mitogen activated protein kinase mediated androgen receptor activation and increased Hif-1α levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 28:1248–1260PubMedPubMedCentral Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R, Meacham RB, Koul HK (2009) Hypoxia associated p38 mitogen activated protein kinase mediated androgen receptor activation and increased Hif-1α levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 28:1248–1260PubMedPubMedCentral
Zurück zum Zitat Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, Lawrence T, Otsu K, Brissette JL, Arthur JS, Park JM (2008) The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 9:1019–1027PubMedPubMedCentral Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, Lawrence T, Otsu K, Brissette JL, Arthur JS, Park JM (2008) The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 9:1019–1027PubMedPubMedCentral
Zurück zum Zitat Kneilling M, Hultner L, Pichler BJ, Mailhammer R, Morawietz L, Solomon S, Eichner M, Sabatino J, Biedermann T, Krenn V, Weber WA, Illges H, Haubner R, Rocken M (2007) Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 56:1806–1816PubMed Kneilling M, Hultner L, Pichler BJ, Mailhammer R, Morawietz L, Solomon S, Eichner M, Sabatino J, Biedermann T, Krenn V, Weber WA, Illges H, Haubner R, Rocken M (2007) Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 56:1806–1816PubMed
Zurück zum Zitat Koeberle SC, Romir J, Fischer S, Koeberle A, Schattel V, Albrecht W, Grutter C, Werz O, Rauh D, Stehle T, Laufer SA (2012) Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat Chem Biol 8:141–143 Koeberle SC, Romir J, Fischer S, Koeberle A, Schattel V, Albrecht W, Grutter C, Werz O, Rauh D, Stehle T, Laufer SA (2012) Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat Chem Biol 8:141–143
Zurück zum Zitat Konisti S, Kiriakidis S, Paleolog EM (2012) Hypoxia—a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol 8:153–162PubMed Konisti S, Kiriakidis S, Paleolog EM (2012) Hypoxia—a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol 8:153–162PubMed
Zurück zum Zitat Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10:451–461PubMed Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10:451–461PubMed
Zurück zum Zitat Krementsov DN, Thornton TM, Teuscher C, Rincon M (2013) The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models. Mol Cell Biol 33:3728–3734PubMedPubMedCentral Krementsov DN, Thornton TM, Teuscher C, Rincon M (2013) The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models. Mol Cell Biol 33:3728–3734PubMedPubMedCentral
Zurück zum Zitat Lee JC, Laydon JT, Mcdonnell PC, Gallagher TF, Kumar S, Green D, Mcnulty D, Blumenthal MJ, Heys JR, Landvatter SW et al (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739–746PubMed Lee JC, Laydon JT, Mcdonnell PC, Gallagher TF, Kumar S, Green D, Mcnulty D, Blumenthal MJ, Heys JR, Landvatter SW et al (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739–746PubMed
Zurück zum Zitat Li C, Beavis P, Palfreeman AC, Amjadi P, Kennedy A, Brennan FM (2011) Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor. Immunology 132:104–110PubMedPubMedCentral Li C, Beavis P, Palfreeman AC, Amjadi P, Kennedy A, Brennan FM (2011) Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor. Immunology 132:104–110PubMedPubMedCentral
Zurück zum Zitat Martin JH, Mohit AA, Miller CA (1996) Developmental expression in the mouse nervous system of the p493F12 SAP kinase. Mol Brain Res 35:47–57PubMed Martin JH, Mohit AA, Miller CA (1996) Developmental expression in the mouse nervous system of the p493F12 SAP kinase. Mol Brain Res 35:47–57PubMed
Zurück zum Zitat Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275:31155–31161PubMed Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275:31155–31161PubMed
Zurück zum Zitat Mavropoulos A, Rigopoulou EI, Liaskos C, Bogdanos DP, Sakkas LI (2013) The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev Immunol 2013:569751PubMedPubMedCentral Mavropoulos A, Rigopoulou EI, Liaskos C, Bogdanos DP, Sakkas LI (2013) The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev Immunol 2013:569751PubMedPubMedCentral
Zurück zum Zitat Mcinnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219PubMed Mcinnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219PubMed
Zurück zum Zitat Meier FM, Mcinnes IB (2014) Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol 28:605–624PubMed Meier FM, Mcinnes IB (2014) Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol 28:605–624PubMed
Zurück zum Zitat Mion F, Tonon S, Toffoletto B, Cesselli D, Pucillo CE, Vitale G (2014) IL-10 production by B cells is differentially regulated by immune-mediated and infectious stimuli and requires p38 activation. Mol Immunol 62:266–276PubMed Mion F, Tonon S, Toffoletto B, Cesselli D, Pucillo CE, Vitale G (2014) IL-10 production by B cells is differentially regulated by immune-mediated and infectious stimuli and requires p38 activation. Mol Immunol 62:266–276PubMed
Zurück zum Zitat Mnich SJ, Blanner PM, Hu LG, Shaffer AF, Happa FA, O’neil S, Ukairo O, Weiss D, Welsh E, Storer C, Mbalaviele G, Ichijo H, Monahan JB, Hardy MM, Eda H (2010) Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis. Int Immunopharmacol 10:1170–1176PubMed Mnich SJ, Blanner PM, Hu LG, Shaffer AF, Happa FA, O’neil S, Ukairo O, Weiss D, Welsh E, Storer C, Mbalaviele G, Ichijo H, Monahan JB, Hardy MM, Eda H (2010) Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis. Int Immunopharmacol 10:1170–1176PubMed
Zurück zum Zitat Monach P, Hattori K, Huang H, Hyatt E, Morse J, Nguyen L, Ortiz-Lopez A, Wu HJ, Mathis D, Benoist C (2007) The K/BxN mouse model of inflammatory arthritis: theory and practice. Methods Mol Med 136:269–282PubMed Monach P, Hattori K, Huang H, Hyatt E, Morse J, Nguyen L, Ortiz-Lopez A, Wu HJ, Mathis D, Benoist C (2007) The K/BxN mouse model of inflammatory arthritis: theory and practice. Methods Mol Med 136:269–282PubMed
Zurück zum Zitat Mountz JM, Alavi A, Mountz JD (2012) Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis. Nat Rev Rheumatol 8:719–728PubMed Mountz JM, Alavi A, Mountz JD (2012) Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis. Nat Rev Rheumatol 8:719–728PubMed
Zurück zum Zitat Nandakumar KS, Holmdahl R (2006) Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 8:223PubMed Nandakumar KS, Holmdahl R (2006) Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 8:223PubMed
Zurück zum Zitat Nikas SN, Drosos AA (2004) SCIO-469 Scios Inc. Curr Opin Investig Drugs 5:1205–1212PubMed Nikas SN, Drosos AA (2004) SCIO-469 Scios Inc. Curr Opin Investig Drugs 5:1205–1212PubMed
Zurück zum Zitat Nunn A, Linder K, Strauss HW (1995) Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 22:265–280PubMed Nunn A, Linder K, Strauss HW (1995) Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 22:265–280PubMed
Zurück zum Zitat Paunovic V, Harnett MM (2013) Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis. Drugs 73:101–115PubMed Paunovic V, Harnett MM (2013) Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis. Drugs 73:101–115PubMed
Zurück zum Zitat Pi X, Wu Y, Ferguson JE, Portbury AL, Patterson C (2009) SDF-1α stimulates JNK3 activity via eNOS-dependent nitrosylation of MKP7 to enhance endothelial migration. Proc Natl Acad Sci USA 106:5675–5680PubMed Pi X, Wu Y, Ferguson JE, Portbury AL, Patterson C (2009) SDF-1α stimulates JNK3 activity via eNOS-dependent nitrosylation of MKP7 to enhance endothelial migration. Proc Natl Acad Sci USA 106:5675–5680PubMed
Zurück zum Zitat Pierre K, Christiane B, Hartmut J, Stefan L (2008) Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles. J Med Chem 51:5630–5640 Pierre K, Christiane B, Hartmut J, Stefan L (2008) Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles. J Med Chem 51:5630–5640
Zurück zum Zitat Rudalska R, Dauch D, Longerich T, Mcjunkin K, Wuestefeld T, Kang T-W, Hohmeyer A, Pesic M, Leibold J, Von Thun A, Schirmacher P, Zuber J, Weiss K-H, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L (2014) In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 20:1138–1146PubMedPubMedCentral Rudalska R, Dauch D, Longerich T, Mcjunkin K, Wuestefeld T, Kang T-W, Hohmeyer A, Pesic M, Leibold J, Von Thun A, Schirmacher P, Zuber J, Weiss K-H, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L (2014) In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 20:1138–1146PubMedPubMedCentral
Zurück zum Zitat Sanchez A, Tripathy D, Yin X, Desobry K, Martinez J, Riley J, Gay D, Luo J, Grammas P (2012) p38 MAPK: a mediator of hypoxia-induced cerebrovascular inflammation. J Alzheimers Dis 32:587–597PubMed Sanchez A, Tripathy D, Yin X, Desobry K, Martinez J, Riley J, Gay D, Luo J, Grammas P (2012) p38 MAPK: a mediator of hypoxia-induced cerebrovascular inflammation. J Alzheimers Dis 32:587–597PubMed
Zurück zum Zitat Saraiva M, O’garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170–181PubMed Saraiva M, O’garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170–181PubMed
Zurück zum Zitat Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O’garra A (2009) Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31:209–219PubMedPubMedCentral Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O’garra A (2009) Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31:209–219PubMedPubMedCentral
Zurück zum Zitat Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G (2000) Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43:2501–2512PubMed Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G (2000) Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43:2501–2512PubMed
Zurück zum Zitat Schett G, Zwerina J, Firestein G (2008) The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67:909–916PubMed Schett G, Zwerina J, Firestein G (2008) The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67:909–916PubMed
Zurück zum Zitat Schreiber S, Feagan B, D’haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J (2006) Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4:325–334PubMed Schreiber S, Feagan B, D’haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J (2006) Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4:325–334PubMed
Zurück zum Zitat Smolen JS, Aletaha D (2011) Monitoring rheumatoid arthritis. Curr Opin Rheumatol 23:252–258PubMed Smolen JS, Aletaha D (2011) Monitoring rheumatoid arthritis. Curr Opin Rheumatol 23:252–258PubMed
Zurück zum Zitat Thalhamer T, Mcgrath MA, Harnett MM (2008) MAPKs and their relevance to arthritis and inflammation. Rheumatology 47:409–414PubMed Thalhamer T, Mcgrath MA, Harnett MM (2008) MAPKs and their relevance to arthritis and inflammation. Rheumatology 47:409–414PubMed
Zurück zum Zitat Tokuda H, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O (2004) Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem 91:1053–1061PubMed Tokuda H, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O (2004) Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem 91:1053–1061PubMed
Zurück zum Zitat Villalvilla A, Gomez R, Roman-Blas JA, Largo R, Herrero-Beaumont G (2014) SDF-1 signaling: a promising target in rheumatic diseases. Expert Opin Ther Targets 18:1077–1087PubMed Villalvilla A, Gomez R, Roman-Blas JA, Largo R, Herrero-Beaumont G (2014) SDF-1 signaling: a promising target in rheumatic diseases. Expert Opin Ther Targets 18:1077–1087PubMed
Zurück zum Zitat Walker JK, Selness SR, Devraj RV, Hepperle ME, Naing W, Shieh H, Kurambail R, Yang S, Flynn DL, Benson AG, Messing DM, Dice T, Kim T, Lindmark RJ, Monahan JB, Portanova J (2010) Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg Med Chem Lett 20:2634–2638PubMed Walker JK, Selness SR, Devraj RV, Hepperle ME, Naing W, Shieh H, Kurambail R, Yang S, Flynn DL, Benson AG, Messing DM, Dice T, Kim T, Lindmark RJ, Monahan JB, Portanova J (2010) Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg Med Chem Lett 20:2634–2638PubMed
Metadaten
Titel
Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis
verfasst von
Philipp Guenthoer
Kerstin Fuchs
Gerald Reischl
Leticia Quintanilla-Martinez
Irene Gonzalez-Menendez
Stefan Laufer
Bernd J. Pichler
Manfred Kneilling
Publikationsdatum
29.04.2019
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 6/2019
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-019-00593-6

Weitere Artikel der Ausgabe 6/2019

Inflammopharmacology 6/2019 Zur Ausgabe